Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

NCT07660094 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-squamous, Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: Aglatimagene Besadenovec
DRUG: Valacyclovir
BIOLOGICAL: Pembrolizumab
DRUG: Docetaxel

Sponsor

Candel Therapeutics, Inc.